美国19岁及以上成人接种13价肺炎球菌结合疫苗(PCV13)上市后监测:疫苗不良事件报告系统(VAERS),2012年6月1日至2015年12月31日
本研究利用美国疫苗不良事件报告系统(VAERS)评估2012年6月至2015年12月期间19岁及以上成人接种PCV13后的不良事件报告。共收到2976份美国成人PCV13报告,其中71%为单独接种PCV13。最常见不良事件为注射部位红斑、疼痛和发热;数据挖掘未发现任何非预期不良事件的报告比例失衡。结论与PCV13上市前研究的安全性数据一致,未发现新的或非预期不良事件。
要点
- VAERS共收到2976份美国成人PCV13报告,71%为单独接种PCV13。
- 19-64岁单独接种者最常见不良事件为注射部位红斑(28%)、注射部位疼痛(24%)和发热(22%)。
- 65岁及以上单独接种者最常见不良事件为注射部位红斑(30%)、红斑(20%)和注射部位肿胀(18%)。
核心结论
- 本研究结果与PCV13上市前研究的安全性数据一致,未发现新的或非预期不良事件。
研究设计与样本
- 利用美国疫苗不良事件报告系统(VAERS)评估2012年6月至2015年12月期间19岁及以上成人接种PCV13后的不良事件报告,包括自动数据分析、对所有严重报告和特殊关注报告的临床审查以及经验贝叶斯数据挖掘。
主要发现
- VAERS共收到2976份美国成人PCV13报告,其中2103份(71%)为单独接种PCV13的报告。
- 14%的报告涉及19-64岁人群,86%涉及65岁及以上人群。
- 19-64岁单独接种者最常见不良事件为注射部位红斑(28%)、注射部位疼痛(24%)和发热(22%)。
- 65岁及以上单独接种者最常见不良事件为注射部位红斑(30%)、红斑(20%)和注射部位肿胀(18%)。
- 非死亡严重报告中最常报告的不良事件:19-64岁为注射部位反应和全身不适;65岁及以上为注射部位反应、全身不适和吉兰-巴雷综合征(表2)。
关键数值与推荐
- 数据挖掘未检测到任何非预期不良事件的报告比例失衡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was first recommended for use in adults aged ⩾19years with immunocompromising conditions in June 2012. On August 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 among adults aged ⩾65years. METHODS: We assessed adverse events (AEs) reports following PCV13 in adults aged ⩾19years reported to the Vaccine Adverse Event Reporting System (VAERS) from June 2012 to December 2015. VAERS is a national spontaneous reporting system for monitoring AEs following vaccination. Our assessment included automated data analysis, clinical review of all serious reports and reports of special interest. We conducted empirical Bayesian data mining to assess for disproportionate reporting. RESULTS: VAERS received 2976 US PCV13 adult reports; 2103 (71%) of these reports were from PCV13 administered alone. Fourteen percent were in persons aged 19-64years and 86% were in persons aged ⩾65years. Injection site erythema (28%), injection site pain (24%) and fever (22%) were the most frequent AEs among persons aged 19-64years; injection site erythema (30%), erythema (20%) and injection site swelling (18%) were the most frequent among persons aged ⩾65years who were given the vaccine alone. The most frequently reported AEs among non-death serious reports were injection site reactions and general malaise among persons 19-64years old; injection site reactions, general malaise and Guillain-Barré syndrome among those ⩾65years (Table 2). Data mining did not detect disproportional reporting for any unexpected AE. CONCLUSIONS: The results of this study were consistent with safety data from pre-licensure studies of PCV13. We did not detect any new or unexpected AEs.
引用
- Haber P, Arana J, Pilishvili T, et al. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015. Vaccine. 2016. PMID: 27836437. doi:10.1016/j.vaccine.2016.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。